Lyra Therapeutics, Inc. · OTC:LYRA
Lyra Therapeutics — 69th Annual Meeting of the American Rhinologic Society (ARS) 2023
12 slides from Lyra Therapeutics's conference presentation, Sep 30, 2023
Slide 1: Evaluation of LYR-220 Corticosteroid Matrices at Week 24 from the BEACON Study in CRS
Evaluation of LYR-220 Corticosteroid Matrices at Week 24 from the BEACON Study in CRS Brent A. Senior, MD1*, Randall A. Ow, MD2, M. Scott Major, MD3, Stacey L. Silvers, MD4, Jeffrey Rosenbloom, MD5, Robert C. Kern, MD6, Lindsay Brayton7, Marina Mihova7, Elaheh Sajjadi, PhD7, Misun Lee, PhD7, Vineeta
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including state
Slide 3: Disclosures
Disclosures • BAS is the Lead Principal Investigator for the Phase 2 BEACON study, consultant for Lyra Therapeutics and Stryker, and VP of Development and Strategy for the ARS. • RAO, MSM, SLS, and JR are principal investigators in the BEACON study. RAO and SLS are consultants for Lyra Therapeutics.
Slide 4: LYR-210 and LYR-220: Investigational Products for CRS
LYR-210 and LYR-220: Investigational Products for CRS • Bioresorbable nasal matrix • Designed to continuously deliver mometasone furoate (7500µg) over 24 weeks to the sinonasal passages • Administered in a straightforward, in-office procedure • LYR-220: For CRS patients with post-surgical anatomy ‒
Slide 5: BEACON: Phase 2 Clinical Study of LYR-220
BEACON: Phase 2 Clinical Study of LYR-220 • CRS patients (polyp and non-polyp) who have BEACON Study Design had a prior bilateral ethmoidectomy • Randomized, blinded, sham-controlled Phase II study to assess safety and efficacy of LYR-220* • Safety endpoint: ‒ Serious adverse events • Key efficacy e
Slide 6: Patient Disposition
BEACON: Patient Disposition 6
Slide 7: Patient Demographics and Baseline Characteristics
BEACON: Patient Demographics and Baseline Characteristics 7
Slide 8: No Serious Adverse Events
BEACON: No Serious Adverse Events Adverse Events occurring in >2 subjects in any group * Includes 3 subjects that received LYR-220-32 in Part 1 of the study 8
Slide 9: Early and Sustained Improvement in SNOT-22
BEACON: Early and Sustained Improvement in SNOT-22 Change from baseline in SNOT-22 total score † p <0.05 9
Slide 10: Statistically Significant Improvements in 3CS
BEACON: Statistically Significant Improvements in 3CS Change from baseline in 3CS † p <0.05 3CS: 3 cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) 10
Slide 11: Statistically Significant Improvements in Individual CS at Week 24
BEACON: Statistically Significant Improvements in Individual CS at Week 24 Error bars represent SE 11
Slide 12: BEACON Study Summary
BEACON Study Summary • Achieved Primary Endpoint: No serious adverse events • Statistically significant improvements in a composite of the 3CS (nasal obstruction, nasal discharge, facial pain/pressure) as early as week 4 (-0.87; p=0.037) and at week 24 (-1.50; p=0.02) ‒ Statistically significant imp
Lyra Therapeutics — 69th Annual Meeting of the American Rhinologic Society (ARS) 2023 on 6ix